A 1982 report of a man with hemophilia dying from pneumocystis pneumonia raised alarms about a potential bloodborne pathogen linked to a new immune syndrome. Despite early warnings, the risks associated with blood transfusions were downplayed, influenced by both a lack of understanding and commercial interests. The controversy surrounding blood safety decisions highlights the complex interplay between public health and the pharmaceutical industry during the AIDS crisis.
